Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 3

Withdrawn

Conditions: Cervical Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-13

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00057928

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States
🇺🇸
Mayo Clinic, Jacksonville, Florida, United States

and more 103 locations

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: three-dimensional conformal radiation therapy

First Posted Date: 2003-04-09

Last Posted Date: 2017-12-22

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 63

Registration Number: NCT00023673

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States

and more 38 locations

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Stage IVB Cervical Cancer
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Recurrent Cervical Carcinoma
Stage IVA Cervical Cancer
Cervical Adenosquamous Carcinoma

Interventions: Drug: Paclitaxel
Drug: Oxaliplatin

First Posted Date: 2003-04-09

Last Posted Date: 2015-11-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00057863

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Completed

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: carboplatin
Drug: fluorouracil
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-03-07

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 56

Registration Number: NCT00022139

Locations: 🇺🇸
Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States

and more 32 locations

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-05-10

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00055887

Locations: 🇨🇦
CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada
🇺🇸
Schiffler Cancer Center, Wheeling, West Virginia, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 19 locations

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Phase 2

Completed

Conditions: Urethral Cancer
Bladder Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-01-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 7

Registration Number: NCT00055835

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States

and more 89 locations

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bryostatin 1
Drug: paclitaxel

First Posted Date: 2003-03-07

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 46

Registration Number: NCT00005028

Locations: 🇺🇸
Wellspan Health - York Cancer Center, York, Pennsylvania, United States
🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

and more 1 locations

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Drug: fluorouracil
Radiation: radiation therapy
Drug: Gemcitabine
Procedure: Radical cystectomy

First Posted Date: 2003-03-07

Last Posted Date: 2018-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 97

Registration Number: NCT00055601

Locations: 🇺🇸
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00054392

Locations: 🇺🇸
Fallon Clinic at Worcester Medical Center, Worcester, Massachusetts, United States
🇺🇸
Aultman Hospital Cancer Center at Aultman Health Foundation, Canton, Ohio, United States
🇺🇸
David Lee Outpatient Cancer Center at Charleston Area Medical Center, Charleston, West Virginia, United States

and more 53 locations

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: oblimersen sodium
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-02-06

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00054548

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy